Correlation between hypoxia and the oxygen sensing pathway in acute myeloid leukemia cells

doi:10.3760/cma.j.cn371439-20230605-00096

Abstract

Abstract:

Hypoxia is one of the significant characteristics of the microenvironment of malignant tumors in the blood system. Hypoxic microenvironment can promote the metastasis and infiltration of tumor cells, which is one of the key factors leading to treatment tolerance, and also an important factor for resistance against tumor immune response. In acute myeloid leukemia （AML）, the cellular oxygen sensing pathway is an important signaling transduction pathway that participates in the cell’s response to hypoxic environments and can regulate biological processes such as metabolism, growth， and survival. Starting from how hypoxia affects the oxygen sensing pathway of leukemia cells, and targeting the cell adaptation mechanism induced by hypoxia, exploring new directions for targeted treatment of hematological malignancies in hypoxic environments can provide new ideas and theoretical support for the treatment of AML.

Key words: Hypoxia, Acute myeloid leukemia, Targeted therapy

Wang Ting, Li Wenqian, Xie Youbang. Correlation between hypoxia and the oxygen sensing pathway in acute myeloid leukemia cells[J]. Journal of International Oncology, 2023, 50(8): 503-507.

References 29

[1]	Yi M, Li A, Zhou L, et al. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017[J]. J Hematol Oncol, 2020, 13(1): 72. DOI:10.1186/s13045-020-00908-z.
[2]	Kim HS, Ha HS, Kim DH, et al. O₂ variant chip to simulate site-specific skeletogenesis from hypoxic bone marrow[J]. Sci Adv, 2023, 9(12): eadd4210. DOI:10.1126/sciadv.add4210.
[3]	Kessler T, Koschmieder S, Schliemann C, et al. Phase Ⅱ clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)[J]. Ann Hematol, 2019, 98(6): 1393-1401. DOI:10.1007/s00277-019-03651-9.
[4]	Christodoulou C, Spencer JA, Yeh SA, et al. Live-animal imaging of native haematopoietic stem and progenitor cells[J]. Nature, 2020, 578(7794): 278-283. DOI:10.1038/s41586-020-1971-z.
[5]	Yao Y, Li F, Huang J, et al. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development[J]. Exp Hematol Oncol, 2021, 10(1): 39. DOI:10.1186/s40164-021-00233-2. pmid: 34246314
[6]	Drolle H, Wagner M, Vasold J, et al. Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy[J]. Leuk Res, 2015, 39(7): 779-785. DOI:10.1016/j.leukres.2015.04.019.
[7]	Li Y, Zhao L, Li XF. The hypoxia-activated prodrug TH-302: exploiting hypoxia in cancer therapy[J]. Front Pharmacol, 2021, 12: 636892. DOI:10.3389/fphar.2021.636892.
[8]	李凡, 何海萍, 张丽华, 等. 骨髓增生异常综合征患者来源间充质干细胞的最新研究进展[J]. 中国实验血液学杂志, 2022, 30(4): 1286-1290. DOI:10.19746/j.cnki.issn1009-2137.2022.04.051.
[9]	Deynoux M, Sunter N, Hérault O, et al. Hypoxia and hypoxia-inducible factors in leukemias[J]. Front Oncol, 2016, 6: 41. DOI:10.3389/fonc.2016.00041. pmid: 26955619
[10]	陈曦, 母丹, 严钦, 等. 骨髓微环境与白血病细胞分化[J]. 国际肿瘤学杂志, 2021, 48(3): 189-192. DOI:10.3760/cma.j.cn371439-20200619-00038.
[11]	Ruan Y, Kim HN, Ogana H, et al. Wnt signaling in leukemia and its bone marrow microenvironment[J]. Int J Mol Sci, 2020, 21(17): 6247. DOI:10.3390/ijms21176247.
[12]	Gruszka AM, Valli D, Alcalay M. Wnt signalling in acute myeloid leukaemia[J]. Cells, 2019, 8(11): 1403. DOI:10.3390/cells8111403.
[13]	Bruno S, Mancini M, De Santis S, et al. The role of hypoxic bone marrow microenvironment in acute myeloid leukemia and future therapeutic opportunities[J]. Int J Mol Sci, 2021, 22(13): 6857. DOI:10.3390/ijms22136857.
[14]	Jiang M, He G, Wang J, et al. Hypoxia induces inflammatory microenvironment by priming specific macrophage polarization and modifies LSC behaviour via VEGF-HIF1α signalling[J]. Transl Pediatr, 2021, 10(7): 1792-1804. DOI:10.21037/tp-21-86. pmid: 34430427
[15]	Kim JW, Tchernyshyov I, Semenza GL, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia[J]. Cell Metab, 2006, 3(3): 177-185. DOI:10.1016/j.cmet.2006.02.002.
[16]	Morganti C, Cabezas-Wallscheid N, Ito K. Metabolic regulation of hematopoietic stem cells[J]. Hemasphere, 2022, 6(7): e740. DOI:10.1097/HS9.0000000000000740. pmid: 35785147
[17]	He P, Lei J, Zou LX, et al. Effects of hypoxia on DNA hydroxymethylase Tet methylcytosine dioxygenase 2 in a KG-1 human acute myeloid leukemia cell line and its mechanism[J]. Oncol Lett, 2021, 22(4): 692. DOI:10.3892/ol.2021.12953. pmid: 34457047
[18]	Abdul-Aziz AM, Shafat MS, Sun Y, et al. HIF1α drives chemokine factor pro-tumoral signaling pathways in acute myeloid leukemia[J]. Oncogene, 2018, 37(20): 2676-2686. DOI:10.1038/s41388-018-0151-1. pmid: 29487418
[19]	Abdul-Aziz AM, Shafat MS, Mehta TK, et al. MIF-induced stromal PKCβ/IL8 is essential in human acute myeloid leukemia[J]. Cancer Res, 2017, 77(2): 303-311. DOI:10.1158/0008-5472.CAN-16-1095. pmid: 27872094
[20]	Jabari M, Allahbakhshian Farsani M, Salari S, et al. Hypoxia-inducible factor1-Α (HIF1α) and vascular endothelial growth factor-A (VEGF-A) expression in De Novo AML patients[J]. Asian Pac J Cancer Prev, 2019, 20(3): 705-710. DOI:10.31557/APJCP.2019.20.3.705.
[21]	Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology[J]. Cell Metab, 2018, 27(2): 281-298. DOI:10.1016/j.cmet.2017.10.005. pmid: 29129785
[22]	Magliulo D, Bernardi R. HIF-α factors as potential therapeutic targets in leukemia[J]. Expert Opin Ther Targets, 2018, 22(11): 917-928. DOI:10.1080/14728222.2018.1538357.
[23]	Nair R, Salinas-Illarena A, Baldauf HM. New strategies to treat AML: novel insights into AML survival pathways and combination therapies[J]. Leukemia, 2021, 35(2): 299-311. DOI:10.1038/s41375-020-01069-1. pmid: 33122849
[24]	Du W, Lu C, Zhu X, et al. Prognostic significance of CXCR4 expression in acute myeloid leukemia[J]. Cancer Med, 2019, 8(15): 6595-6603. DOI:10.1002/cam4.2535.
[25]	Ladikou EE, Chevassut T, Pepper CJ, et al. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia[J]. Br J Haematol, 2020, 189(5): 815-825. DOI:10.1111/bjh.16456.
[26]	Vitale C, Griggio V, Riganti C, et al. Targeting HIF-1α regulatory pathways as a strategy to hamper tumor-microenvironment interactions in CLL[J]. Cancers (Basel), 2021, 13(12): 2883. DOI:10.3390/cancers13122883.
[27]	Cheng Y, Ma XL, Wei YQ, et al. Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases[J]. Biochim Biophys Acta Rev Cancer, 2019, 1871(2): 289-312. DOI:10.1016/j.bbcan.2019.01.005.
[28]	Cheng H, Huang C, Xu X, et al. PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia[J]. J Transl Med, 2017, 15(1): 179. DOI:10.1186/s12967-017-1287-4. pmid: 28851457
[29]	Li L, Zhao L, Man J, et al. CXCL2 benefits acute myeloid leukemia cells in hypoxia[J]. Int J Lab Hematol, 2021, 43(5): 1085-1092. DOI:10.1111/ijlh.13512. pmid: 33793061